Virus Microneutralization Assay Data Analysis for Vaccine Development, Enhancement and Efficacy Improvement

This CDC generated invention entails improved methods of analyzing microneutralization assays, especially for the purposes of determining specific antibody concentrations and optimizing vaccine formulation. More specifically, the invention is a set of SAS based programs using 4-parameter logistic curve fitting algorithms to interpolate between individual data points, allowing for enhanced accuracy and precision when establishing neutralization titers. This method allows every experiment to be analyzed the same way, provides greater accuracy by interpolating curve fits between dilutions, prevents transcription errors or manual calculation errors, develops and applies consistent quantitative control rules, and improves operational speed and efficiency.

Potential Commercial Applications:		Competitive Advantages:
Commerical virus vaccine evaluation and strain selection Virus strain surveillance programs Harmonize data analysis and standardize reporting procedures for improved worldwide, health-programs cohesion		Demonstrated improvements in accuracy and precision calculating virus microneutralization titers Programs produce structured datasets allowing for rapid report generation and high-level analyses Useful for improved strain selection in future influenza (or other) vaccine development

Development Stage:

• In vitro data available
• In situ data available (on-site)

Inventors:

Jarad Schiffer (CDC)  ➽ more inventions...

Kathy Hancock (CDC)  ➽ more inventions...


Intellectual Property:
US Application No. 61/357,413
PCT Application No. PCT/US2011/041459
US Application No. 13/700,978

Publications:
Klimov A, et al. PMID 22528152
Vequilla V, et al. PMID 21471339

Licensing Contact:
Admin. Licensing Specialist (ALS),
Email:
Phone:

OTT Reference No: E-262-2013-0
Updated: Jan 27, 2014